Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSNASDAQ:KLTONASDAQ:PLRZNASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03$0.04$0.00▼$0.78$1.28M1.188,400 shs59 shsKLTOKlotho Neurosciences$0.17-3.8%$0.22$0.11▼$8.11$4.85M-1.1568,762 shs149,917 shsPLRZPolyrizon$0.67-11.7%$0.52$0.25▼$4.80$2.81MN/A5.09 million shs1.76 million shsSNGXSoligenix$1.92+1.3%$2.13$1.68▼$14.83$4.81M2.06760,685 shs9,750 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-9.91%0.00%+5.08%-94.55%KLTOKlotho Neurosciences+6.24%+6.24%+16.37%-49.83%+18,059,900.00%PLRZPolyrizon-33.46%+147.10%+119.25%-35.16%+75,859,900.00%SNGXSoligenix-2.83%-4.55%+2.71%-18.19%-71.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ASNGXSoligenix0.2513 of 5 stars0.02.00.00.00.40.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AKLTOKlotho Neurosciences 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ASNGXSoligenix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.39N/AN/A($2.06) per share-0.01KLTOKlotho NeurosciencesN/AN/A$0.18 per share0.95($2.16) per shareN/APLRZPolyrizonN/AN/AN/AN/AN/AN/ASNGXSoligenix$840K5.72N/AN/A$3.83 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AKLTOKlotho Neurosciences$1.35MN/A0.00∞N/AN/AN/A-25.89%N/APLRZPolyrizonN/AN/A0.00∞N/AN/AN/AN/AN/ASNGXSoligenix-$6.14M-$6.11N/AN/AN/A-1,473.38%-223.29%-74.18%5/9/2025 (Estimated)Latest ADXS, SNGX, PLRZ, and KLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025N/ASNGXSoligenix-$0.67N/AN/AN/AN/AN/A3/31/2025Q4 2024KLTOKlotho NeurosciencesN/A-$0.07N/A-$0.07N/AN/A3/21/2025Full YearSNGXSoligenix-$0.95-$1.14-$0.19-$1.14$0.20 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AKLTOKlotho NeurosciencesN/A0.160.16PLRZPolyrizonN/AN/AN/ASNGXSoligenixN/A2.282.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%KLTOKlotho Neurosciences20.07%PLRZPolyrizonN/ASNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%KLTOKlotho Neurosciences2.00%PLRZPolyrizonN/ASNGXSoligenix2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableKLTOKlotho NeurosciencesN/A28.01 million26.54 millionN/APLRZPolyrizonN/A4.19 millionN/AN/ASNGXSoligenix202.51 million2.44 millionNot OptionableADXS, SNGX, PLRZ, and KLTO HeadlinesRecent News About These CompaniesIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.May 7 at 8:41 AM | finance.yahoo.comSoligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 30, 2025 | msn.comSolgenix shares rise on positive skin cancer treatment resultsApril 24, 2025 | investing.comFireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.April 24, 2025 | msn.comEQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 24, 2025 | markets.businessinsider.comSNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…April 15, 2025 | msn.comPositive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 WeeksApril 14, 2025 | prnewswire.comSoligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma TreatmentApril 3, 2025 | theglobeandmail.comSoligenix Reports Publication Describing Preclinical Efficacy Of CiVax - Quick FactsMarch 27, 2025 | nasdaq.comSoligenix selects IBN to spearhead corporate communicationsMarch 26, 2025 | markets.businessinsider.comSNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…March 26, 2025 | msn.comSoligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 26, 2025 | medindia.netIBN Initiates Coverage of Soligenix Inc.March 25, 2025 | globenewswire.comSoligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 25, 2025 | prnewswire.comSoligenix Trumps Year-End FinancialsMarch 21, 2025 | baystreet.caSoligenix Announces Recent Accomplishments and Year End 2024 Financial ResultsMarch 21, 2025 | prnewswire.comWhy Soligenix (NASDAQ: SNGX) Is ‘One to Watch’March 20, 2025 | theglobeandmail.comHyBryte™ Treatment Studies Presented at Two Medical Conferences in MarchMarch 6, 2025 | prnewswire.comSoligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 26, 2025 | msn.comEQS-News: Soligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXS, SNGX, PLRZ, and KLTO Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.03 0.00 (0.00%) As of 05/6/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Klotho Neurosciences NASDAQ:KLTO$0.17 -0.01 (-3.78%) As of 12:32 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Polyrizon NASDAQ:PLRZ$0.67 -0.09 (-11.68%) As of 12:45 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.Soligenix NASDAQ:SNGX$1.92 +0.03 (+1.33%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
